HighVista Strategies LLC Buys 167,983 Shares of Evolus, Inc. $EOLS

HighVista Strategies LLC raised its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 289.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 226,025 shares of the company’s stock after buying an additional 167,983 shares during the period. HighVista Strategies LLC owned about 0.35% of Evolus worth $1,388,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of EOLS. Frazier Life Sciences Management L.P. bought a new stake in shares of Evolus in the second quarter worth $22,431,000. Soleus Capital Management L.P. boosted its position in Evolus by 96.4% in the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after purchasing an additional 1,039,842 shares during the last quarter. Caligan Partners LP boosted its position in Evolus by 23.8% in the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock worth $25,413,000 after purchasing an additional 796,973 shares during the last quarter. First Light Asset Management LLC bought a new stake in shares of Evolus during the 2nd quarter valued at about $4,795,000. Finally, Frontier Capital Management Co. LLC increased its position in shares of Evolus by 37.9% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company’s stock valued at $15,333,000 after purchasing an additional 457,533 shares during the last quarter. 90.69% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

EOLS has been the subject of several recent research reports. Stifel Nicolaus cut their target price on shares of Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Mizuho set a $15.00 price target on shares of Evolus in a research note on Wednesday, February 4th. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. BTIG Research restated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the transaction, the insider directly owned 354,388 shares in the company, valued at $2,533,874.20. The trade was a 2.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.10% of the stock is owned by insiders.

Evolus Price Performance

Shares of NASDAQ EOLS opened at $5.01 on Monday. The stock has a market cap of $325.95 million, a PE ratio of -6.19 and a beta of 1.02. Evolus, Inc. has a 1 year low of $4.09 and a 1 year high of $13.66. The firm has a fifty day moving average price of $4.89 and a 200-day moving average price of $6.13.

Evolus (NASDAQ:EOLS) last released its earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The company had revenue of $90.30 million for the quarter, compared to the consensus estimate of $89.58 million. On average, research analysts expect that Evolus, Inc. will post -0.61 EPS for the current year.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.